EU watchdog to assess availability of drugs made at Catalent sites sold to Novo
07/02/2024 16:53
FRANKFURT, Feb 7 (Reuters) - The European Union's drugs regulator said on Wednesday it will assess the impact on the availability of medicines processed at Catalent CTLT.N sites that will be sold to Novo Nordisk NOVOb.CO . (Reporting by Ludwig Burger) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
Recent news on Catalent
See all newsBrief: Novo Holdings Completes Acquisition Of Catalent
Novo Nordisk rises as Catalent deal in US nears
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
Brief: Catalent And Novo Holdings Fulfill All Regulatory Closing Conditions For Pending Transaction
Brief: Novo Nordisk Says All Regulatory Closing Conditions Relating To Review Of Novo Holdings A/S's Pending Acquisition Of Catalent Have Been Fulfilled